Imprimis receives FDA warning over eye medication advertising
January 16, 2018 at 16:59 PM EST
Jan 16 (Reuters) - The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.